BridgeBio Pharma Inc BBIO
$81.50 $1.39 (1.68%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
BBIO Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, BridgeBio Pharma Inc is classified as halal.
HALAL
Report Source: undefined Quarter Report
BridgeBio Pharma Inc. Stock Analysis BBIO
United States Health Care Large Cap BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. The company is headquartered in Palo Alto, California and currently employs 834 full-time employees. The company went IPO on 2019-06-27. The company discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. The company also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
BridgeBio Pharma Inc (BBIO) Chart
Financial Metrics & Statements of BridgeBio Pharma Inc (BBIO)
FAQ's for BridgeBio Pharma Inc (BBIO)
- As of August 2026, BridgeBio Pharma Inc BBIO is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes BridgeBio Pharma Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in BridgeBio Pharma Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of BridgeBio Pharma Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of BridgeBio Pharma Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of BridgeBio Pharma Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Related Halal Stocks to BridgeBio Pharma Inc (BBIO)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
